MIST

Milestone Pharmaceuticals Inc

Milestone Pharmaceuticals (NASDAQ:MIST) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 13. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-13-milestone-pharmaceuticals-inc-stock...

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) saw a large increase in short interest in the month of April. As of April 15th, there was short interest totaling 10,325,577 shares, an...

Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) have been assigned an average rating of "Moderate Buy" from the six brokerages that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has...

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) CEO Joseph Oliveto sold 36,500 shares of the firm's stock in a transaction dated Thursday, April 16th. The stock was sold at an average...

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) CEO Joseph Oliveto sold 36,500 shares of the firm's stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $2.26, for a total value of $82,490.00. Following the completion of the sale, the chief...

Raymond James Financial raised Milestone Pharmaceuticals to a "strong-buy" rating in a research note on Thursday...

Wall Street Zen downgraded shares of Milestone Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday...

Raymond James Financial began coverage on Milestone Pharmaceuticals in a report on Friday. They issued a "strong-buy" rating and a $6.00 price objective on the stock...

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) has been assigned an average recommendation of "Hold" from the six ratings firms that are currently covering the company, Marketbeat.com...